TY - JOUR
T1 - Minibeam Radiation Therapy Treatment (MBRT)
T2 - Commissioning and First Clinical Implementation
AU - Grams, Michael P.
AU - Mateus, Chrystian Quintero
AU - Mashayekhi, Maryam
AU - Mutter, Robert W.
AU - Djonov, Valentin
AU - Fazzari, Jennifer M.
AU - Xiao, Huaping
AU - Frechette, Kelsey M.
AU - Wentworth, Adam J.
AU - Morris, Jonathan M.
AU - Klebel, Brandon
AU - Thull, Jack C.
AU - Guenzel, Rachael M.
AU - Wismayer, David J.Schembri
AU - Lucien, Fabrice
AU - Park, Sean S.
AU - Lester, Scott C.
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/12/1
Y1 - 2024/12/1
N2 - Purpose: Minibeam radiation therapy (MBRT) is characterized by the delivery of submillimeter-wide regions of high “peak” and low “valley” doses throughout a tumor. Preclinical studies have long shown the promise of this technique, and we report here the first clinical implementation of MBRT. Methods and Materials: A clinical orthovoltage unit was commissioned for MBRT patient treatments using 3-, 4-, 5-, 8-, and 10-cm diameter cones. The 180 kVp output was spatially separated into minibeams using a tungsten collimator with 0.5 mm wide slits spaced 1.1 mm on center. Percentage depth dose (PDD) measurements were obtained using film dosimetry and plastic water for both peak and valley doses. PDDs were measured on the central axis for offsets of 0, 0.5, and 1 cm. The peak-to-valley ratio was calculated at each depth for all cones and offsets. To mitigate the effects of patient motion on delivered dose, patient-specific 3-dimensional-printed collimator holders were created. These conformed to the unique anatomy of each patient and affixed the tungsten collimator directly to the body. Two patients were treated with MBRT; both received 2 fractions. Results: Peak PDDs decreased gradually with depth. Valley PDDs initially increased slightly with depth, then decreased gradually beyond 2 cm. The peak-to-valley ratios were highest at the surface for smaller cone sizes and offsets. In vivo film dosimetry confirmed a distinct delineation of peak and valley doses in both patients treated with MBRT with no dose blurring. Both patients experienced prompt improvement in symptoms and tumor response. Conclusions: We report commissioning results, treatment processes, and the first 2 patients treated with MBRT using a clinical orthovoltage unit. While demonstrating the feasibility of this approach is a crucial first step toward wider translation, clinical trials are needed to further establish safety and efficacy.
AB - Purpose: Minibeam radiation therapy (MBRT) is characterized by the delivery of submillimeter-wide regions of high “peak” and low “valley” doses throughout a tumor. Preclinical studies have long shown the promise of this technique, and we report here the first clinical implementation of MBRT. Methods and Materials: A clinical orthovoltage unit was commissioned for MBRT patient treatments using 3-, 4-, 5-, 8-, and 10-cm diameter cones. The 180 kVp output was spatially separated into minibeams using a tungsten collimator with 0.5 mm wide slits spaced 1.1 mm on center. Percentage depth dose (PDD) measurements were obtained using film dosimetry and plastic water for both peak and valley doses. PDDs were measured on the central axis for offsets of 0, 0.5, and 1 cm. The peak-to-valley ratio was calculated at each depth for all cones and offsets. To mitigate the effects of patient motion on delivered dose, patient-specific 3-dimensional-printed collimator holders were created. These conformed to the unique anatomy of each patient and affixed the tungsten collimator directly to the body. Two patients were treated with MBRT; both received 2 fractions. Results: Peak PDDs decreased gradually with depth. Valley PDDs initially increased slightly with depth, then decreased gradually beyond 2 cm. The peak-to-valley ratios were highest at the surface for smaller cone sizes and offsets. In vivo film dosimetry confirmed a distinct delineation of peak and valley doses in both patients treated with MBRT with no dose blurring. Both patients experienced prompt improvement in symptoms and tumor response. Conclusions: We report commissioning results, treatment processes, and the first 2 patients treated with MBRT using a clinical orthovoltage unit. While demonstrating the feasibility of this approach is a crucial first step toward wider translation, clinical trials are needed to further establish safety and efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85199961197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85199961197&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2024.06.035
DO - 10.1016/j.ijrobp.2024.06.035
M3 - Article
C2 - 39002850
AN - SCOPUS:85199961197
SN - 0360-3016
VL - 120
SP - 1423
EP - 1434
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 5
ER -